CLINICAL_TRIALS
trial_result
· 2026-03-10
Clinical Trial Update: Daratumumab in STK11 Mutated NSCLC [Phase 2]
Summary
A Phase 2 clinical trial evaluating daratumumab in non-small cell lung cancer with STK11/LKB1 mutations has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NYU Langone Health | Conditions: Non-small Cell Lung Cancer With STK11/LKB1 Mutation | Phase 2 | Status: COMPLETED